Why rheumatoid arthritis pain may persist even when inflammation is under control

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-27T13:59:52.336Z • Permanent link

Researchers at the University of California, San Francisco, have made a groundbreaking discovery that sheds light on the complex nature of rheumatoid arthritis pain. Led by Dr. Kristin R. Larson, a renowned rheumatologist, the study found that even after inflammation is under control, pain and fatigue can persist in patients. The research team analyzed data from over 1,000 patients and identified several hidden drivers that contribute to sustained symptoms.

These drivers include depression, poor sleep, obesity, smoking, and chronic pain. Dr. Larson explained that these factors can exacerbate the condition, making it challenging for patients to manage their symptoms. The study's findings have significant implications for the development of new treatments and therapies that target these underlying drivers. The researchers are now working with pharmaceutical companies to explore potential new products that address these complex issues.

The study's results are based on data from the Rheumatoid Arthritis Research Registry, a comprehensive database that tracks patient outcomes and treatment responses. The registry is maintained by the National Institutes of Health and includes data from over 100,000 patients. The researchers also collaborated with the pharmaceutical company, Biogen, to analyze patient responses to its rheumatoid arthritis treatment, Rituximab.

The study's findings have significant implications for the pharmaceutical industry, particularly for companies that develop treatments for rheumatoid arthritis. Companies such as Biogen and Pfizer are major players in the rheumatoid arthritis market, and their products are used by millions of patients worldwide. The identification of hidden drivers of pain and fatigue could lead to the development of new products that address these complex issues.

The research community is also eager to see how the study's findings will impact the development of new treatments. Researchers at institutions such as the University of Oxford and Harvard Medical School are already exploring new approaches to treating rheumatoid arthritis, including the use of stem cells and gene therapy. The study's results could provide valuable insights into these emerging approaches and help to accelerate the development of new treatments.

The study's findings are part of a larger pattern of research that highlights the complexities of rheumatoid arthritis. In recent years, there has been a growing recognition of the need for a more nuanced understanding of the condition, one that takes into account the complex interplay between inflammation, pain, and other factors. This approach is reflected in the work of researchers such as Dr. Lars Fabel, who has written extensively on the topic of rheumatoid arthritis and its treatment.